- Home
- RXT vs SVRA Comparison
RXT vs SVRA Comparison
Compare RXT & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXT
- SVRA
- Stock Information
- Founded
- RXT 1998
- SVRA N/A
- Country
- RXT United States
- SVRA United States
- Employees
- RXT N/A
- SVRA N/A
- Industry
- RXT EDP Services
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- RXT Technology
- SVRA Health Care
- Exchange
- RXT Nasdaq
- SVRA Nasdaq
- Market Cap
- RXT 524.5M
- SVRA 540.6M
- IPO Year
- RXT 2020
- SVRA N/A
- Fundamental
- Price
- RXT $2.45
- SVRA $2.80
- Analyst Decision
- RXT Hold
- SVRA Buy
- Analyst Count
- RXT 6
- SVRA 7
- Target Price
- RXT $2.47
- SVRA $9.86
- AVG Volume (30 Days)
- RXT 761.3K
- SVRA 966.0K
- Earning Date
- RXT 03-11-2025
- SVRA 03-06-2025
- Dividend Yield
- RXT N/A
- SVRA N/A
- EPS Growth
- RXT N/A
- SVRA N/A
- EPS
- RXT N/A
- SVRA N/A
- Revenue
- RXT $2,771,200,000.00
- SVRA N/A
- Revenue This Year
- RXT N/A
- SVRA N/A
- Revenue Next Year
- RXT N/A
- SVRA N/A
- P/E Ratio
- RXT N/A
- SVRA N/A
- Revenue Growth
- RXT N/A
- SVRA N/A
- 52 Week Low
- RXT $1.45
- SVRA $2.60
- 52 Week High
- RXT $3.41
- SVRA $5.70
- Technical
- Relative Strength Index (RSI)
- RXT 53.77
- SVRA 39.71
- Support Level
- RXT $2.31
- SVRA $2.60
- Resistance Level
- RXT $2.53
- SVRA $3.14
- Average True Range (ATR)
- RXT 0.16
- SVRA 0.17
- MACD
- RXT 0.03
- SVRA -0.01
- Stochastic Oscillator
- RXT 61.82
- SVRA 32.79
About RXT Rackspace Technology Inc.
Rackspace Technology Inc is an end-to-end, hybrid, multi cloud technology services company. It designs, builds and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services; Data; Colocation; Cloud; Managed Hosting; Professional Services; and Security & Compliance. It operates in segments namely, Private Cloud, and Public Cloud. It generates revenue through the sale of consumption-based contracts for its service offerings and from the sale of professional services related to designing and building custom solutions.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.